Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Phase 3

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Rituximab
Drug: Placebo
Drug: Lenalidomide

First Posted Date: 2013-09-10

Last Posted Date: 2023-02-22

Lead Sponsor: Celgene

Target Recruit Count: 358

Registration Number: NCT01938001

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Arlington Cancer Center, Arlington, Texas, United States
🇨🇳
Beijing Cancer Hospital, Beijing, PR, China

and more 157 locations

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

Phase 2

Completed

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: MLN9708
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2013-09-06

Last Posted Date: 2023-08-03

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 42

Registration Number: NCT01936532

Locations: 🇫🇷
CHRU - Hôpitaux de Brabois, Vandoeuvre Les Nancy, France
🇫🇷
CHRU Dijon, Dijon, France
🇫🇷
CHRU - Hôpital du Haut Lévêque, Bordeaux, France

and more 7 locations

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Not Applicable

Terminated

Conditions: Myeloma

Interventions: Drug: Thalidomide
Drug: Lenalidomide
Behavioral: Questionnaires

First Posted Date: 2013-08-23

Last Posted Date: 2019-04-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01927718

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Hematologic Disorder

Interventions: Drug: Lenalidomide
Biological: Influenza Vaccine
Biological: Pneumovax Vaccine

First Posted Date: 2013-08-16

Last Posted Date: 2018-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01924169

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Phase 1

Completed

Conditions: B-Cell Non-Hodgkin Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Leukemia
Lymphoma
Plasma Cell Myeloma
T-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Ipilimumab
Drug: Lenalidomide

First Posted Date: 2013-08-09

Last Posted Date: 2024-12-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 41

Registration Number: NCT01919619

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma (MM)

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2013-08-08

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01919086

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: lenalidomide
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2013-07-22

Last Posted Date: 2018-10-29

Lead Sponsor: Stanford University

Target Recruit Count: 17

Registration Number: NCT01904643

Locations: 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Phase 3

Terminated

Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Biological: Elotuzumab

First Posted Date: 2013-07-03

Last Posted Date: 2021-07-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT01891643

Locations: 🇺🇸
Crescent City Research Consortium, LLC, Marrero, Louisiana, United States
🇺🇸
Illinois Cancercare, Pc, Peoria, Illinois, United States
🇺🇸
Memorial Cancer Institute, Hollywood, Florida, United States

and more 7 locations

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Recurrent B-Cell Prolymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Small Lymphocytic Lymphoma
Refractory B-Cell Prolymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia

Interventions: Drug: Ibrutinib
Drug: Lenalidomide

First Posted Date: 2013-06-26

Last Posted Date: 2022-09-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT01886859

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2013-06-20

Last Posted Date: 2022-11-14

Lead Sponsor: Amgen

Target Recruit Count: 22

Registration Number: NCT01881789

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Providence St. Joseph's Hospital, Burbank, California, United States
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy